This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
by Derek Lewis
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
by Zacks Equity Research
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
by Ekta Bagri
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more room for growth, and any dip in share price can be used as a buying opportunity.
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FVD
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Company News for Nov 1, 2024
by Zacks Equity Research
Companies In The Article Are: MET,CI, BMY, MO
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
by Zacks Equity Research
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
Initial Claims Lower-Than-Expected
by Zacks Equity Research
Initial Claims Lower-Than-Expected
Un-spooky Halloween: PCE, Jobless Claims Tame
by Mark Vickery
It's hard to wish for a more in-line PCE report, especially considering it's the preferred print on inflation for the Fed.
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 20.81% and 5.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Markets Give Back Gains as Hovering Continues
by Mark Vickery
As we've stated in this space previously, the big news the market is waiting for is not here yet.
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
by Zacks Equity Research
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
by Ekta Bagri
BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Myriad (MYGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curious about Bristol Myers (BMY) Q3 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.92, signifying a -0.26% move from its prior day's close.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.